专利快速检索-快速检索全球专利，免费商用专利数据库-IPRDB

1. 发明申请

WO2013076501A2 SCREENING METHOD 审中-公开
标题翻译：筛选方法
公开(公告)号：WO2013076501A2
公开(公告)日：2013-05-30
申请号：PCT/GB2012/052905
申请日：2012-11-23
申请人： QUEEN MARY AND WESTFIELD COLLEGE UNIVERSITY OF LONDON
发明人： VANHAESEBROECK, Bart , BILANGES, Benoit , ALLIOUACHENE, Samira , CHAUSSADE, Claire
IPC分类号： G01N33/68 , G01N33/50
CPC分类号： G01N33/6893 , G01N33/5041 , G01N2800/042 , G01N2800/044
摘要： The present invention provides a method for identifying agents useful in the treatment and/or prevention of a disease associated with insulin resistance and/or glucose intolerance which comprises the step of investigating the capacity of a test agent to inhibit the Vps34 signalling pathway and/or the ΡΙ3Κ-02β signalling pathway. The present invention also provides a transgenic non-human animal which comprises a mutation in the gene encoding Vps34 or ΡΙ3Κ-C2β such that the active site is inactivated.
摘要翻译：本发明提供了一种用于鉴定可用于治疗和/或预防与胰岛素抵抗和/或葡萄糖不耐受相关的疾病的药物的方法，该方法包括：检测试剂抑制Vps34信号通路和/或 RhoIota3Kappa-02beta信号通路。本发明还提供一种转基因非人动物，其包含编码Vps34或RhoIota3Kappa-C2beta的基因的突变，使得活性位点失活。

2. 发明申请

WO2013064833A1 METHOD FOR REPLICATING HCV IN VITRO 审中-公开
标题翻译：用于在体外替代HCV的方法
公开(公告)号：WO2013064833A1
公开(公告)日：2013-05-10
申请号：PCT/GB2012/052730
申请日：2012-11-02
申请人： QUEEN MARY AND WESTFIELD COLLEGE UNIVERSITY OF LONDON
发明人： FOSTER, Graham , CUNNINGHAM, M.E. , JAVAID, Alia
IPC分类号： C12N5/16 , G01N33/576
CPC分类号： C12N5/16 , C12N7/00 , C12N2510/02 , C12N2770/24211 , C12N2770/24251 , C12N2770/24252 , C12Q1/707 , C12Q2600/136 , C12Q2600/158 , G01N33/5767 , G01N2500/04 , G01N2500/10
摘要： There is provided a method for replicating HCV virus in vitro which comprises the following steps: (i) fusing an HCV-infected white blood cell with a hepatocyte cell to produce a fused cell; and (ii) culturing the fused cell so that HCV replication may occur. There is also provided a fused cell capable of replicating HCV virus in vitro which is made by fusing an HCV-infected white blood cell with a hepatocyte cell, and uses of such a fused cell to screen for anti-HCV drugs and assessing patient responsiveness to therapy before treatment.
摘要翻译：提供了一种体外复制HCV病毒的方法，其包括以下步骤：（i）将HCV感染的白细胞与肝细胞融合以产生融合细胞; 和（ii）培养融合细胞以使HCV复制发生。还提供了能够在体外复制HCV病毒的融合细胞，其通过将HCV感染的白血细胞与肝细胞细胞融合而制备，以及使用这种融合细胞筛选抗HCV药物并评估患者对治疗前治疗。

3. 发明申请

WO2012130478A1 CANCER MARKERS 审中-公开
标题翻译：癌症标志
公开(公告)号：WO2012130478A1
公开(公告)日：2012-10-04
申请号：PCT/EP2012/001477
申请日：2012-03-30
申请人： QUEEN MARY AND WESTFIELD COLLEGE, UNIVERSITY OF LONDON , LORINCZ, Attila
发明人： LORINCZ, Attila
IPC分类号： C12Q1/68
CPC分类号： C12Q1/6886 , C12Q2600/118 , C12Q2600/154
摘要： Hence, the invention relates to a method for diagnosis and/or prognosis of cancer, comprising the steps of analyzing in a sample of a subject the DNA methylation status of a genomic region of at least one member of the group of, (i) SFN according to SEQ ID NO. 1, (ii) SLIT2 according to SEQ ID NO. 2, (iii) SERPINB5 according to SEQ ID NO. 3; and (iv) TWIST 1 according to SEQ ID NO 4; wherein, if (i) SFN shows a methylation cut off value of above 80 % and/or, (ii) SLIT2 shows a methylation cut-off value of above 45 % and/or, (iii) SERPBINB5 shows a methylation cut-off value of above 70 %, and/or (iv) TWIST 1 shows a methylation level below 15 % the sample is categorized as a sample from a patient with cancer and/of a poor prognosis.
摘要翻译：因此，本发明涉及一种用于癌症的诊断和/或预后的方法，包括以下步骤：在受试者的样品中分析以下组中至少一个成员的基因组区域的DNA甲基化状态：（i）SFN 根据SEQ ID NO。 1，（ii）根据SEQ ID NO。 2，（iii）SEQ ID NO：5的SERPINB5。 3; 和（iv）根据SEQ ID NO 4的TWIST 1; 其中，如果（i）SFN显示高于80％的甲基化切断值和/或（ii）SLIT2显示高于45％的甲基化截止值和/或（iii）SERPBINB5显示甲基化截止值值高于70％，和/或（iv）TWIST 1显示甲基化水平低于15％，样品被分类为患有癌症和/或预后不良的患者的样品。

4. 发明申请

WO2012042270A1 ANTIBODY SPECIFICALLY BINDING SYNOVIAL MICROVASCULATURE OF ARTHRITIS PATIENTS 审中-公开
标题翻译：抗体特异性结合性神经病变患者的微血管
公开(公告)号：WO2012042270A1
公开(公告)日：2012-04-05
申请号：PCT/GB2011/051854
申请日：2011-09-30
申请人： QUEEN MARY AND WESTFIELD COLLEGE UNIVERSITY OF LONDON , PITZALIS, Costantino
发明人： PITZALIS, Costantino
IPC分类号： C07K16/18
CPC分类号： C07K16/18 , C07K16/28 , C07K2317/21 , C07K2317/622
摘要： The present invention provides an antigen binding polypeptide which specifically targets the synovial microvasculaturc of arthritis patients and comprises one or more complementarity determining regions (CDRs) selected from the group consisting of SEQ ID NOs 1 to 4. The present invention also relates to the use of such antigen binding polypeptides and conjugates thereof for use in the diagnosis and treatment of arthritis.
摘要翻译：本发明提供了特异性靶向关节炎患者的滑液微血管的抗原结合多肽，并且包含选自SEQ ID NO.1至4的一个或多个互补决定区（CDR）。本发明还涉及使用这种抗原结合多肽及其缀合物用于诊断和治疗关节炎。

5. 发明申请

WO2012140414A1 RHBDF2 VARIANTS AND MALIGNANT OR INFLAMMATORY CONDITIONS 审中-公开
标题翻译： RHBDF2变种和恶性或炎症条件
公开(公告)号：WO2012140414A1
公开(公告)日：2012-10-18
申请号：PCT/GB2012/050777
申请日：2012-04-05
申请人： QUEEN MARY AND WESTFIELD COLLEGE UNIVERSITY OF LONDON , KELSELL, David
发明人： KELSELL, David
IPC分类号： C12Q1/68 , G01N33/50
CPC分类号： C12Q1/6886 , C12Q1/6883 , C12Q2600/156 , C12Q2600/158 , G01N33/5011 , G01N33/57484 , G01N2333/96433
摘要： The present invention provides a polypeptide having an amino acid sequence based on the sequence shown as SEQ ID No. 1 but comprising one or more mutations compared that sequence, whose expression in vivo is associated with tylosis and/or predisposition to develop cancer. The invention also provides a nucleic acid sequence capable of encoding such a polypeptide; a screening method for determining whether a compound may be useful in the treatment of cancer or inflammatory conditions; and a method for diagnosing cancer in a subject, based on the expression of such a polypeptide.
摘要翻译：本发明提供了一种多肽，其具有基于SEQ ID No.1所示的序列的氨基酸序列，但是包含一个或多个突变，其与在体内表达与发生癌症的特发性和/或倾向相关的序列相比较。本发明还提供了能够编码这种多肽的核酸序列; 用于确定化合物是否可用于治疗癌症或炎性病症的筛选方法; 以及基于这样的多肽的表达来诊断受试者的癌症的方法。

6. 发明申请

WO2011064559A2 NOVEL INOSITOL PHOSPHATE DERIVATIVES 审中-公开
标题翻译：新型磺酰胺磷酸盐衍生物
公开(公告)号：WO2011064559A2
公开(公告)日：2011-06-03
申请号：PCT/GB2010/002200
申请日：2010-11-30
申请人： QUEEN MARY AND WESTFIELD COLLEGE, UNIVERSITY OF LONDON , UNIVERSITY OF BATH , FALASCA, Marco , RILEY, Andrew, Michael , GODAGE, Himali, Yasmin , POTTER, Barry, Victor, Lloyd
发明人： FALASCA, Marco , RILEY, Andrew, Michael , GODAGE, Himali, Yasmin , POTTER, Barry, Victor, Lloyd
IPC分类号： A61K31/661 , C07F9/117 , A61P35/00
CPC分类号： C07F9/117 , A61K31/661 , C07F9/65522 , A61K2300/00
摘要： The present invention relates to compounds of the formula (I) wherein R 1 ,R 2 , R 3 , R 4 , R 5 and R 6 , X and n are as defined herein. Preferred compounds are inositol phosphate derivatives wherein R 1 is a substituted or unsubstituted phenyl and at least one of R 2 , R 3 , R 4 , R 5 and R 6 is PO 3 2- Alternative compounds are inositol phosphate derivatives of the formula (I) wherein R 1 is a fiuorophore moiety The compounds are useful alone or in combination with known therapeutic agents for the treatment of diseases, especially cancer.
摘要翻译：本发明涉及式（I）化合物，其中R 1，R 2，R 3，R 4，R 5和R 6，X和n如本文所定义。优选的化合物是肌醇磷酸酯衍生物，其中R 1是取代或未被取代的苯基，并且R 2，R 3，R 4，R 5和R 6中的至少一个是PO 3。2-替代化合物是式（I）的肌醇磷酸酯衍生物，其中R 1是氟离子部分该化合物可单独使用或与用于治疗疾病，特别是癌症的已知治疗剂组合使用。

7. 发明申请

WO2011009892A1 METHOD OF MONITORING THE PERFORMANCE OF A SOFTWARE APPLICATION 审中-公开
标题翻译：监控软件应用性能的方法
公开(公告)号：WO2011009892A1
公开(公告)日：2011-01-27
申请号：PCT/EP2010/060575
申请日：2010-07-21
申请人： QUEEN MARY AND WESTFIELD COLLEGE, UNIVERSITY OF LONDON , PAGE, David John , OGILVIE, Rupert Lawrence Grantham , PITTS, Jonathan Michael
发明人： PAGE, David John , OGILVIE, Rupert Lawrence Grantham , PITTS, Jonathan Michael
IPC分类号： G06F11/34 , H04L12/26
CPC分类号： G06F11/3409 , G06F11/3457 , G06F2201/865 , H04L43/08
摘要： A method of monitoring the level of performance of a software application running on a network-attached computing device, comprises monitoring information exchange at least one station on the network; measuring at least two performance indicator metrics, such as delay, jitter, loss, response time, throughput, goodput, and object size; and deriving an indicator parameter, from a non-linear combination of the indicator metrics. A transformation may be applied to each indicator metric to obtaining a corresponding derived value, and the derived values then additively combined, to obtain the said indicator parameter. The transformation has a first region in which the derived value depends relatively weakly on the corresponding metric, and a second region, in which the derived value depends relatively strongly on the corresponding metric. A score value may be entered by a user, indicative of the user's perception of the performance of the software application, and compared with the derived indicator parameter. The calculation used to derive the indicator parameter may be varied, in dependence on the user-entered score. Diagnostic traces may be triggered in dependence on the derived indicator parameter. Values of the indicator parameter and associated trace data may be collected in a database and collated to diagnose and/or predict problems in the said computer system.
摘要翻译：一种监视在网络连接的计算设备上运行的软件应用程序的性能水平的方法，包括监视网络上的至少一个站的信息交换; 测量至少两个性能指标度量，例如延迟，抖动，丢失，响应时间，吞吐量，输出和对象大小; 以及从指标度量的非线性组合导出指标参数。可以将变换应用于每个指示符度量以获得相应的导出值，然后将导出值加法组合，以获得所述指标参数。该变换具有第一区域，其中导出值相对较弱地依赖于对应的度量，以及第二区域，其中导出值相对强烈地取决于相应的度量。用户可以输入分数值，指示用户对软件应用的表现的感知，并与导出的指标参数进行比较。用于导出指标参数的计算可以根据用户输入的分数而变化。可以根据导出的指示符参数来触发诊断迹线。可以在数据库中收集指示符参数和相关跟踪数据的值，并对其进行整理以诊断和/或预测所述计算机系统中的问题。

8. 发明申请

WO2012013931A1 METHODS FOR DIAGNOSING CANCER 审中-公开
标题翻译：用于诊断癌症的方法
公开(公告)号：WO2012013931A1
公开(公告)日：2012-02-02
申请号：PCT/GB2011/001130
申请日：2011-07-27
申请人： QUEEN MARY AND WESTFIELD COLLEGE UNIVERSITY OF LONDON , TEH, Muy, Teck
发明人： TEH, Muy, Teck
IPC分类号： C12Q1/68
CPC分类号： C12Q1/6886 , C12Q2600/112 , C12Q2600/118 , C12Q2600/16
摘要： Provided are methods for diagnosing cancer in a patient or for identifying a patient at risk of developing cancer. The methods comprise determining the amount of five or more biomarkers selected from HOXA7, AURKA, NEK2, FOXM1B, CCNB1, CEP55, CENPA, DNMT3B, DNMT1, HELLS, MAPK8, BMI1, ITGB1, IVL and CTNNB1 in a sample obtained from a patient and comparing the amount of the determined biomarkers in the sample from the patient to the amount of the biomarkers in or of a normal control. A difference in the amount of the biomarkers in the sample from the patient compared to the amount of the biomarkers in or of the normal control is associated with the presence of cancer or is associated with a risk of developing cancer. Also provided are methods for analysing the differential expression of biomarkers between samples obtained from a patient suffering from or suspected of suffering from cancer and samples obtained from or of a normal control, the method comprising analysing the differential expression using an algorithm. Further provided are kits for use in the methods.
摘要翻译：提供了用于诊断患者中的癌症或用于鉴定患有癌症风险的患者的方法。所述方法包括从患者获得的样品中确定选自HOXA7，AURKA，NEK2，FOXM1B，CCNB1，CEP55，CENPA，DNMT3B，DNMT1，HELLS，MAPK8，BMI1，ITGB1，IVL和CTNNB1中的五种或更多种生物标志物的量，将来自患者的样品中确定的生物标志物的量与正常对照中的生物标志物的量进行比较。与正常对照中的生物标志物的量相比，来自患者的样品中生物标志物的量的差异与癌症的存在相关或与发生癌症的风险相关。还提供了分析从患有或怀疑患有癌症的患者和从正常对照获得的样品获得的样品之间生物标志物的差异表达的方法，所述方法包括使用算法分析差异表达。还提供了用于该方法的试剂盒。

9. 发明申请

WO2010012306A1 HEALTHY KIDNEY BIOMARKERS 审中-公开
标题翻译：健康KIDNEY生物标志
公开(公告)号：WO2010012306A1
公开(公告)日：2010-02-04
申请号：PCT/EP2008/060062
申请日：2008-07-31
申请人： QUEEN MARY AND WESTFIELD COLLEGE, UNIVERSITY OF LONDON , HOSPITAL CLÍNIC I PROVINCIAL DE BARCELONA , INSTITUT DE INVESTIGACIONS BIOMEDIQUES AUGUST PI I SUNYER , QUINTANA PORRAS, Luis, F. , SOLE GONZALEZ, Amanda , BAÑÓN - MANEUS, Elisenda , CAMPISTOL, Josep, M , RODRIGUEZ CUTILLAS, Pedro
发明人： QUINTANA PORRAS, Luis, F. , SOLE GONZALEZ, Amanda , BAÑÓN - MANEUS, Elisenda , CAMPISTOL, Josep, M , RODRIGUEZ CUTILLAS, Pedro
IPC分类号： G01N33/68
CPC分类号： G01N33/6893 , C07K7/18 , C07K14/47 , C07K14/70539 , G01N33/6851 , G01N2800/245 , G01N2800/347
摘要： The invention provides novel healthy kidney biomarkers useful in the monitoring of renal function and in the prognosis and diagnosis of renal dysfunctions, especially those related to graft rejection. The invention further relates to methods for aiding in the evaluation, and design of personalized therapies in transplantation nephrology.
摘要翻译：本发明提供了可用于监测肾功能以及肾功能异常的预后和诊断的新型健康肾生物标志物，特别是与移植物排斥有关的那些。本发明还涉及用于帮助评估和设计移植肾脏学中的个性化疗法的方法。

10. 发明申请

WO2014154874A2 CHLORINE-CONTAINING SILICATE GLASSES AND GLASS CERAMICS 审中-公开
标题翻译：含氯硅酸盐玻璃和玻璃陶瓷
公开(公告)号：WO2014154874A2
公开(公告)日：2014-10-02
申请号：PCT/EP2014/056318
申请日：2014-03-28
申请人： QUEEN MARY AND WESTFIELD COLLEGE UNIVERSITY OF LONDON
发明人： HILL, Robert , KARPUKHINA, Natalia , CHEN, Xiaojing
CPC分类号： A61K8/19 , A61C3/025 , A61K8/25 , A61K2800/74 , A61L27/10 , A61L27/12 , A61L2430/02 , A61Q11/00 , B24C11/00 , C03C1/002 , C03C3/062 , C03C3/11 , C03C3/112 , C03C4/0007 , C03C4/0014 , C03C4/0021 , C03C4/12 , C03C10/00 , C03C10/0009 , C03C10/0063 , C03C10/16 , C03C12/00
摘要： A chlorine-containing silicate glass comprising SiO 2 , at least 0.5 mole percent metal chloride and at least 10 mole percent of MgO, SrO, BaO, and CaO combined.
摘要翻译：包含SiO 2，至少0.5摩尔％金属氯化物和至少10摩尔％的MgO，SrO，BaO和CaO的含氯硅酸盐玻璃组合。

你已经成功收藏专利！

检索式保存成功!

IPRDB

热门服务

关于我们

友情链接

联系方式